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ORIGINAL RESEARCH

Assessing the Accuracy, Quality, and Readability of
Patient Accessible Online Resources Regarding
Ocular Gene Therapy and Voretigene Neparvovec

Swetha Davuluri 1
Nicolas A Yannuzzi 1
Amy Kloosterboer 1
Ajay E Kuriyan 2
Jayanth Sridhar 1
1
Department of Ophthalmology, Bascom
Palmer Eye Institute, University of Miami
Miller School of Medicine, Miami, FL,
USA; 2Department of Retina Service,
Mid-Atlantic Retina, Wills Eye Hospital,
Thomas Jefferson University, Philadelphia,
PA, USA

Purpose: To evaluate the accuracy, quality, and readability of online information regarding
the Food and Drug Administration (FDA) approved ocular gene therapy voretigene nepar
vovec (Luxturna, Spark Therapeutics, Philadelphia, PA, USA).
Methods: Ten online resources about voretigene neparvovec were assessed in this crosssectional study. A novel 25-question assessment was created to evaluate the information most
relevant to patients. Each article was assessed by independent graders using the assessment
and the DISCERN instrument. An online readability tool, Readable, was used to assess
readability. Accountability was evaluated using the Journal of the American Medical
Association (JAMA) benchmarks.
Results: The average questionnaire score for all the articles was 33.93 (SD 11.21, CI 95%
±6.95) out of 100 possible points with significant variation in the content accuracy and
quality between the articles (P=0.017). EyeWiki achieved the highest score and
MedicineNet the lowest. The mean reading grade for all articles was 12.88 (SD 1.93, CI
95% ±1.19) with significant variation between articles (P=0.001). Wikipedia was the most
readable, and the FDA website was the least. None of the articles achieved all four JAMA
benchmarks, and only one of the ten articles, EyeWiki, achieved three of the four JAMA
benchmarks.
Conclusion: The information available online regarding this FDA-approved ocular gene
therapy is generally of low quality, above the average reading level of the general population,
and varies significantly between sources. The articles provide incomplete information that is
not entirely accurate or easy to read, and as a result, the material would not support patients
adequately in their medical decisions and questions about this new therapeutic option.
Keywords: gene therapy, patient education, vitreoretinal surgery, leber congenital
amaurosis, voretigene neparvovec
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Gene augmentation therapy is a technique in which genetic material is intro
duced into a patient’s cells to treat or prevent disease.1 Gene therapy was
introduced in human subjects in the early 1990s, and currently, it is being
recognized as a promising treatment option for multiple diseases.2 Several
trials have been conducted or are ongoing to evaluate the efficacy and safety
of gene therapy, including but not limited to hematopoietic stem cell based
gene therapy for β-thalassemia major, liver-directed gene therapy for hemo
philia B, and T-cell immunotherapy for acute lymphoblastic leukemia.2,3
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Gene therapy has been of particular interest in ophthal
mology. It has been studied in years of experimentation to
determine its use to treat several ocular conditions includ
ing neovascularization, retinitis pigmentosa, Stargardt dis
ease, retinoblastoma, and more.4 In 2017, voretigene
neparvovec (Luxturna, Spark Therapeutics, Philadelphia,
PA, USA) became the third gene therapy to be approved
by the Food and Drug Administration (FDA).5 Voretigene
neparvovec was unanimously approved by the FDA for
patients with the biallelic RPE65 gene mutation form of
hereditary retinal dystrophy.5 In the pivotal study, patients
with this inherited retinal dystrophy were treated with
subretinal injections of voretigene neparvovec and showed
improvement in their functional vision which persisted for
at least 4 years.6,7
With the approval of voretigene and the subsequent
press coverage, patients with eye conditions are likely to
learn about treatment options on the internet. Millions of
Americans search health-related information and seek
medical advice online every day.8 Previous research
shows about 62% of Internet users search the internet for
health information.8 The content acquired online influ
ences patients’ health decisions.9 The content patients
encounter would ideally be easy to comprehend. Most
patients read at an eighth grade level; however, most
sources of medical information are written at a tenth
grade level or higher.10 Low health literacy has been
associated with poor medication adherence and adverse
outcomes such as uncontrolled chronic disease and
increased hospitalizations.11 For these reasons, it is critical
that the information patients obtain is accurate, complete,
and easy to understand. As such, the goal of this study is to
assess the accuracy, quality, and readability of online
information regarding ocular applications of this gene
therapy.

Methods
Article Selection and Content Analysis
The keywords “eye gene therapy” or “voretigene neparvo
vec” or “Luxturna” were entered in Google.com and in
major medical websites such as the American Academy of
Ophthalmology (AAO) website, and relevant articles were
selected for analysis from the top search results with exclu
sion of similar results from the same organization.
Preference was given to articles of formal as well as com
mercial organizations trusted by ophthalmologists and those
believed to be regularly accessed by patients such as
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Wikipedia. The chosen articles included ones from the
AAO,12 American Optometric Association (AOA),13
EyeWiki,14 US Food and Drug Administration (FDA),15
Spark Therapeutics,16 MedicineNet,17 National Eye
Institute (NEI),18 Novartis,19 WebMD,20 and Wikipedia.21
A twenty-five question grading tool was designed by two
vitreoretinal surgeons (JS and AEK) to assess the accuracy
and quality of patient-relevant information in each article
(Table 1). The questions were chosen to match presumed
typical questions a patient or patient family member would
ask and potential topic discussion when considering treat
ment with voretigene neparvovec. The evaluation of each
website was completed independently by two vitreoretinal
surgeons (JS and AEK) and one vitreoretinal surgery fellow
(NY). A grading scale from 0–4, with 4 as a maximum, was
utilized to evaluate each question as detailed in Table 1.
A score of 0 was given if there was no information provided
regarding the question. A score of 1 indicated the response
was unclear, had inaccurate information, omitted significant
information, and was very poorly organized. A score of 2
was for partial answers that somewhat addressed the con
cept but had gaps in the information and organization.
A score of 3 meant the article provided essential elements
to answer the question, addressed the most relevant points,
and was focus and organized. A maximum score of 4
indicated the answer was accurate and thorough; the article
provided a clear answer that was well explained, focused,
and organized. Each article was independently graded by
each observer, and interobserver reproducibility was
assessed with a Spearman correlation. The average score
between the three graders was used to compare the quality
of the articles.
The articles were further evaluated by two graders (JS
and NY) using the DISCERN instrument. DISCERN is
widely used to determine the quality of health information
provided to patients.22 Each article was independently
graded using the 16-question tool. Each question is rated
using a 5-point scale ranging from “No” to “Yes.” A score of
1 is given if the answer to the question is “No.” A score of 5
is given if the answer is a definite “Yes.” Scores of 2 through
4 are given if the article meets the criterion of the question
partially. The interobserver reproducibility was determined
with a Spearman correlation. The average score between the
two graders was used to compare the quality of the articles.

Accountability Analysis
The accountability of each article was evaluated using the
Journal of the American Medical Association (JAMA)

Clinical Ophthalmology 2021:15

Powered by TCPDF (www.tcpdf.org)

Clinical Ophthalmology 2021:15
2.00
0.00
0.00
0.00
0.00
1.00

Does gene therapy cure the conditions it is used to treat?

At what age may gene therapy be administered?
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What are the potential risks associated with gene therapy?

What is the price of gene therapy?
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1.67

What is RPE65?

What is a pars plana vitrectomy with a subretinal injection?
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Are all patients with Leber’s Congenital Amaurosis eligible for gene
therapy?
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What is Leber’s Congenital Amaurosis?

Are there FDA approved gene therapies delivered through intravitreal
injection?
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What is retinal dystrophy?
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Table 1 Questionnaire to Assess Online Resources Describing Ocular Gene Therapy with Mean and Total Scores
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2.00
0.00
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1.25
0.49

Are there FDA approved gene therapies delivered through pars plana
vitrectomy with a subretinal injection?

How long can results of treatment last?

Are repeat treatments of gene therapy necessary?

Is there gene therapy available for retinitis pigmentosa?

Is there gene therapy available for Stargardt’s disease?

Total Points, Max 100

Points, Mean

SD

95% CI

0.38

0.96

0.72

18.00

0.00

0.00

0.00

0.00

1.33

AOAc

0.67

1.71

2.05

51.33

0.33

0.67

0.00

0.00

4.00

EyeWiki

0.56

1.44

1.63

40.67

0.33

0.33

0.00

0.33

2.67

FDAd

0.33

0.85

0.67

16.67

0.00

0.00

0.00

0.00

0.00
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0.00
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1.20

30.00

0.00
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0.33

Novartis
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1.53
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49.67

0.00

0.67

0.67

0.00

2.67
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Spark

0.48

1.21

1.21

30.33

0.00

0.00

1.00

0.67

1.33

WebMD

0.53

1.34

1.65

41.33

0.33

1.33

0.00

0.00

0.67

Wikipedia

Notes: aScores of individual questions scaled from 0–4. bAmerican Academy of Ophthalmology. cAmerican Optometric Association. dU.S. Food and Drug Administration. eNational Eye Institute. Table 1 displays the 25 questions
designed to assess accuracy and quality of each article along with the mean number of points each article received for each question. A grading scale from 0–4, with 4 as a maximum, was used to evaluate each question. Each score in the
table is the average of three scores given by three independent graders.
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benchmarks.23 Each article was assessed for the 4 stan
dards: Authorship, attributions, disclosure, and currency.
Each article should include the authors and contributors
along with their affiliations and relevant credentials to
meet the authorship requirements outlined by JAMA.
Attributions, or references, should be reported, and disclo
sures and currency, or date of update, should be specified.

Readability Analysis
The online tool, Readable, was used to analyze readability
of the articles.24 Each article was assessed using the
Flesch Reading Ease Score (FRE), Flesch Kincaid
Grade Level, Gunning Fox Index, Coleman Liau Index,
and Simple Measure of Gobbledygook (SMOG) Index.
The Flesch Reading Ease Score awards each article
a score from 0–100 based on total words, sentences, and
syllables in the text. Higher scores translate to better
readability. A score between 70 to 80 is comparable to
an eighth-grade reading level. The Flesch Kincaid Grade
Level, Gunning Fox Index, Coleman Liau Index, and
SMOG Index are separate readability formulas which
report the reading level required to understand the text.
Each index states the US grade level of education
reflected by the article. The mean score of these indices
corresponds to the numerical US grade level. Therefore,
a mean score of 12 indicates a 12th grade reading level
while a score above 12 corresponds to a college reading
level.

Davuluri et al

Results
Article Selection and Content Analysis
Ten articles were analyzed for the study. The interobserver reproducibility was statistically significant
between JS and AEK (r=0.66, P=0.038) and between JS
and NY (r=0.84, P=0.003) and approached statistical sig
nificance between AEK and NY (r=0.62, P=0.058). The
average questionnaire score for all the articles was 33.93
(SD 11.21, CI 95% ±6.95) out of 100 possible points.
There was a statistically significant difference in the con
tent accuracy and quality between the articles (P=0.017).
The top scoring article was EyeWiki with an average score
of 51.33 points. MedicineNet was the lowest scoring arti
cle with an average score of 16.67 points (Table 2). There
was a statistically significant difference in the articles’
scores on each of the 25 questions (P<0.001).
For the DISCERN instrument, the inter-observer repro
ducibility was statistically significant between the two
graders (r=0.89, P<0.001). The average score for all of
the articles with this grading tool was 45.20 (SD 8.40, CI
95% ±5.21) out of 80 possible points. Results of the
instrument also showed a statistically significant difference
in the content quality between the articles (P=0.043), with
EyeWiki scoring highest with an average score of 60.00

Table 2 Mean and Total Scores for Grading Online Resources
Describing Ocular Gene Therapy

Statistical Analysis
Statistical analysis was completed using IBM SPSS
Statistics for Mac, version 25.0, released 2017 (Armonk,
NY: IBM Corp). Content analysis using the 25-question
assessment and the DISCERN instrument was performed
by treating the data as ordinal variables and analyzing with
the Kruskal–Wallis test. A post-hoc Dunn-Bonferroni test
was used to determine pairwise comparisons. Statistical
significance was set at P≤0.05 for the main comparisons
and the pairwise comparisons. The readability analysis
was conducted using a Kruskal–Wallis test to compare
the mean reading grade level for each article. A post-hoc
Dunn-Bonferroni test was used to determine pairwise
comparisons. A Spearman correlation test was carried out
to evaluate correlation between accuracy and readability.
Statistical significance was set at P≤0.05 for the main
comparisons, Spearman correlation, and pairwise
comparisons.

Clinical Ophthalmology 2021:15

Total

Points,

Pointsa

Mean

SD

EyeWiki

51.33

2.05

1.71

0.67

Spark Therapeutics

49.67

1.99

1.53

0.60

Wikipedia

41.33

1.65

1.34

0.53

b

FDA

40.67

1.63

1.44

0.56

AAOc

32.00

1.28

1.25

0.49

WebMD

30.33

1.21

1.21

0.48

Novartis

30.00

1.20

1.31

0.51

NEId

29.33

1.17

1.33

0.52

18.00

0.72

0.96

0.38

0.67

0.85

0.33

e

AOA

MedicineNet
a

16.67
b

Notes: Out of a possible 100 points. U.S. Food and Drug Administration.
c
American Academy of Ophthalmology. dNational Eye Institute. eAmerican
Optometric Association. Table 2 displays the total scores each of the 10 articles
received on the 25-question assessment in order from highest to lowest score.
These scores were obtained using the average score between three independent
graders.
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Table 3 Mean and Total Scores for Online Sources Describing
Ocular Gene Therapy Graded Using the DISCERN Instrument
Total

Points,

Pointsa

Mean

SD

CI 95%

EyeWiki

60.00

3.75

1.27

0.62

Spark Therapeutics

54.50

3.41

1.34

0.66

FDAb

53.00

3.31

1.21

0.59

Wikipedia

47.50

2.97

1.18

0.58

46.00

2.88

1.02

0.50

NEId

41.50

2.59

1.06

0.52

Novartis

41.00

2.56

1.12

0.55

AOAe

39.50

2.47

0.89

0.44

WebMD

39.00

2.44

0.97

0.47

MedicineNet

30.00

1.88

0.89

0.44

AAO

c

a

b

Notes: Out of a possible 80 points. U.S. Food and Drug Administration.
c
American Academy of Ophthalmology. dNational Eye Institute. eAmerican
Optometric Association. Table 3 displays the total scores each article received on
the 16-question DISCERN instrument in order from highest to lowest score. These
scores were obtained using the average score between two independent graders.

points and MedicineNet scoring lowest with 30.00 points
(Table 3). There was a statistically significant correlation
between the articles’ scores on the 25-question grading
scale and on the DISCERN instrument (r=0.90, P<0.001).

Accountability Analysis
None of the articles achieved all 4 JAMA benchmarks.
One of the 10 (10%) articles, EyeWiki, achieved 3 of the 4
JAMA benchmarks (Table 4). Currency was the most
displayed benchmark followed by attribution and author
ship. There was no correlation between the accuracy of the
articles and JAMA benchmarks (r=−0.229, P=0.524).

Readability Analysis
The mean Flesch Reading Ease Score for all the articles
was 39.51 (SD 9.98, CI 95% ±6.19). The mean reading
grade for all websites was 12.88 (SD 1.93, CI 95% ±1.19).
There was no significant correlation between the FRE
score and mean reading grade level (r=−0.340, P=0.336).
There was a significant difference between the mean read
ing grade level of the websites (P=0.001). Wikipedia had
the lowest mean reading grade level of 9.63, and the FDA
website had the highest mean reading grade level of 16.73.
Wikipedia (P=0.005) and the Spark Therapeutics product
website (P=0.015) had significantly lower reading levels
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Table 4 JAMA Benchmarks Achieved by Online Sources
Regarding Ocular Gene Therapy
JAMA Benchmarks

N (%)

4 Benchmarks

0 (0%)

3 Benchmarks

a

1 (10%)

2 Benchmarks

3 (30%)

1 Benchmark

5 (50%)

0 Benchmarksb

1 (10%)

Attribution

4 (40%)

Authorship

4 (40%)

Currency

6 (60%)

Disclosure

0 (0%)

Notes: aEyeWiki achieved 3 of the 4 benchmarks. bSpark Therapeutics achieved 0
of the 4 benchmarks. Table 4 displays the number of articles that achieved JAMA
benchmarks and the most common benchmarks displayed by the articles. Each
article was assessed for the 4 standards as determined by JAMA: Authorship,
attributions, disclosure, and currency.

than the FDA website (Table 5). There was no significant
correlation between website accuracy and the mean read
ing grade (r=−0.444, p=0.199).

Discussion
The results (Table 6) demonstrated that there was signifi
cant variation in the quality, accuracy, and readability of
the information available to patients about the ocular gene
therapy voretigene neparvovec. EyeWiki provided the
most complete and accurate information of the articles
analyzed and achieved the most benchmarks of all the
articles fulfilling 3 of the 4 benchmarks. However,
EyeWiki had a mean reading grade level of 12.85, and is
difficult to read for a layperson, as it is primarily designed
for ocular provider education rather than patient consump
tion. Still, given that it is freely available and accessible by
the public, it was included in the analysis.
The second-highest scoring resource on both grading
tools was the Spark Therapeutics patient informational
website regarding voretigene neparvovec; it was
the second most readable article as well with a mean read
ing grade level of 10.40. Nevertheless, it scored only 54.50
out of 80 points on the DISCERN grading tool and below
50 out of 100 points on average on the 25-question assess
ment. It did not achieve any of the JAMA benchmarks;
moreover, despite being the highest scoring resource
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Table 5 Readability Analysis of Online Sources Describing Ocular Gene Therapy
Readability

Wikipedia

Spark Therapeutics

AAOa

EyeWiki

MedicineNet

NEIb

AOAc

WebMD

Novartis

FDAd

Flesch Reading Ease

37.6

53.5

50.4

21.8

42.5

41.2

46.2

45.2

32

24.7

Mean Reading Grade

9.63

10.40

11.45

12.85

13.03

13.03

13.63

13.75

14.35

16.73

Mean Reading Grade SD

1.22

1.05

0.90

1.03

0.93

0.92

1.91

1.39

0.96

1.76

Mean Reading Grade

1.20

1.03

0.88

1.01

0.91

0.90

1.87

1.36

0.94

1.72

CI (95%)
Notes: aAmerican Academy of Ophthalmology. bNational Eye Institute. cAmerican Optometric Association. dU.S. Food and Drug Administration. Table 5 displays the mean
readability scores as determined for each article by the online tool, Readable, and reported in increasing mean reading grade order. The Flesch Kincaid Grade Level, Gunning
Fox Index, Coleman Liau Index, and SMOG Index state a US reading grade level. The mean score of these indices was used to determine the numerical grade level of the
article. A mean reading grade of 12 indicates a 12th grade reading level while a score above 12 corresponds to a college reading level.

Table 6 Summary Table of Grading Indices Used to Assess Online Sources Describing Ocular Gene Therapy
Article Source

25-Question Assessment
Total Pointsa

DISCERN Instrument
Total Pointsb

Number of JAMA
Benchmarks Achievedc

Mean Reading
Graded

AAOe

32.00

46.00

1

11.45

AOA

18.00

39.50

1

13.63

EyeWiki

51.33

60.00

3

12.85

FDAg

40.67

53.00

1

16.73

MedicineNet

16.67

30.00

2

13.03

NEIh

29.33

41.50

2

13.03

Novartis

30.00

41.00

2

14.35

Spark Therapeutics

49.67

54.50

0

10.40

WebMD

30.33

39.00

1

13.75

Wikipedia

41.33

1

9.63

f

a

47.50
b

c

Notes: Out of a possible 100 points. Out of a possible 80 points. Out of a possible 4 benchmarks. Average of 4 indices reporting US reading grade levels. eAmerican
Academy of Ophthalmology. fAmerican Optometric Association. gU.S. Food and Drug Administration. hNational Eye Institute. Table 6 provides a summary of all the grading
indices used in assessing the articles including the 25-question assessment, the DISCERN instrument, the number of JAMA benchmarks achieved, and the mean reading
grade. The total points on the 25-question assessment is the average score between three independent graders. The total points on the DISCERN instrument is the average
score between two independent graders. The number of JAMA benchmarks achieved quantifies the number each article met of the 4 JAMA benchmarks: Authorship,
attributions, disclosure, and currency. The mean reading grade states a US reading grade level with a mean score of 12 reflecting a 12th grade reading level while a score
above 12 corresponds to a college reading level.

designed for reading by patients, it is not an ideal source of
reference given the potential inherent conflict of interest
present in the manufacturing company’s discussion of its
own product.25
In this study, the information available from formal
organizations such as the FDA, AAO, and NEI was of
overall low quality. Ideally, these major organizations
would have accurate and complete information that is
easy to understand as many patients rely on these institu
tions for medical knowledge. Prior studies have shown
that educated patients have greater trust in federal agencies
and community organizations as sources of medical
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information.26 Overall, patients prefer non-commercial
websites especially from established organizations such
as the FDA and NEI over other sources.27,28 The FDA
website received the highest content and DISCERN aver
age score of these three resources; however, it had a mean
reading grade level of 16.73, the highest level of all the
articles. Although the AAO and NEI websites were easier
to read with mean reading levels of 11.45 and 13.03,
respectively, both resources scored poorly on both scales.
Furthermore, the AAO and FDA websites only achieved 1
of the 4 JAMA benchmarks while NEI achieved 2 of the 4
benchmarks demonstrating the overall poor accountability
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of the articles, although one could argue that the organiza
tion as a whole may be taking accountability for the
content, which would not be identified by the JAMA
benchmark scoring.
This study was limited in several aspects. The 25question assessment was based on two retina providers'
experience and assumptions regarding typical patient ques
tions and was not validated in a patient population.
Furthermore, the inter-observer correlation between two
pairs of the graders resulted in moderate strength of corre
lation demonstrating variability in interpretation of the
articles or of the grading scale. To further test the online
resources being evaluated, the standardized DISCERN
instrument was also incorporated, and there was
a significant and strong positive correlation between the
DISCERN scores and the content assessment scores. Interobserver reproducibility had greater strength in the
DISCERN instrument as well. Patients may use search
engines or keywords that vary from the ones used to
determine websites included in this study. Some resources
included in this study were found beyond the second
results page on Google, but patients often only use the
first two results pages for their research.28 These resources
were still included given their importance as prominent,
public organizations (eg NEI, FDA). The resources eval
uated were non-peer reviewed sources of varied websites
including commercial, government, and non-government
organizations. These articles were chosen as they were
readily available during search, but patients may prefer
to read peer reviewed sources or information from other
organizations. Resources were not directly assessed by
patients; future studies could further study online resource
quality and content by directly evaluating patients’
comprehension.
In conclusion, this study demonstrated that patient
accessible online resources regarding the ocular gene ther
apy voretigene neparvovec are generally incomplete, diffi
cult to read, and of poor quality. The available material
varied significantly by source and did not provide adequate
information to aid patients in their medical decisions. This
indicates an unfilled need to create patient-friendly online
content regarding this ocular gene therapy as available
research and therapeutic options continue to evolve.
Future articles can be improved by assuring accuracy of
the information using peer reviewed research papers as
reference and by maintaining a reading level sufficient
for patients’ understanding.
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